Baseline characteristics of patients with MDR-TB undergoing surgery (n = 121)
| Characteristic | |
|---|---|
| BMI, body mass index; FEV1, forced expiratory volume in 1 s; INH, isoniazid; RIF, rifampin; EMB, ethambutol; PZA, pyrazinamide; SM, ??; KM, kanamycin; CM, ??; CS, ??; PAS, ?? | |
| *Bilateral disease is defined as involvement in both lungs, excluding small nodules or subsegmental scarring. | |
| †Positive culture includes any patient with persistent positive culture after at least 4 months of treatment. | |
| Median (range) age (years) | 27 (16–66) |
| No (%) male | 80 (66.1) |
| Median (range) number of prior treatments (n = 115) | 3 (0–9) |
| Median (range) number of months in current treatment before surgery (n = 120) | 15 (0.6–41) |
| Median (range) number of drugs to which resistance documented | 7 (3–11) |
| Resistance to: | |
| INH (n = 119) | 119 (100) |
| RIF (n = 119) | 119 (100) |
| EMB (n = 119) | 115 (96.6) |
| PZA (n = 118) | 94 (79.7) |
| SM (n = 118) | 100 (84.8) |
| KM (n = 115) | 60 (52.2) |
| CM (n = 111) | 41 (36.9) |
| Fluoroquinolone (n = 112) | 31 (27.7) |
| Ethionamide (n = 114) | 78 (68.4) |
| CS (n = 112) | 1 (0.9) |
| PAS (n = 99) | 21 (21.2) |
| Massive haemoptysis (n = 119) | 35 (29.4) |
| Bilateral disease* | 53 (43.8) |
| Type of lesion (preoperative) | |
| Cavitary disease | 111 (91.7) |
| Bronchiestasis | 27 (22.9) |
| Bronchopleural fistula | 4 (3.4) |
| Pleural empyema | 5 (4.2) |
| Fibrosis and scarring | 101 (83.5) |
| Bilateral cavitary disease | 20 (17.4) |
| Baseline low BMI | 38 (31.4) |
| Preoperative low BMI | 43 (35.5) |
| Vital capacity <50% | 22 (18.2) |
| FEV1 (ml) (n = 118) | |
| 800–1000 | 2 (1.7) |
| 1001–2000 | 59 (50.0) |
| >2000 | 57 (48.3) |
| Comorbid disease | 23 (19.0) |
| HIV | 1 (0.8) |
| Alcoholism and/or drug dependency | 11 (9.1) |
| Tobacco use | 8 (6.7) |
| Diabetes mellitus | 6 (5.0) |
| Chronic renal insufficiency | 1 (0.8) |
| Aspergilloma | 6 (5.0) |
| Positive culture status at time of surgery† | 96 (79.3) |